Michael L. Blum - 23 Feb 2023 Form 4 Insider Report for Homology Medicines, Inc. (QTTB)

Reporting relationship: Chief Commercial Officer
Issuer ticker: QTTB
Reported as of: 23 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Feb 2023, 15:05:45 UTC
Prior SEC filing: 20 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Paul Alloway, Attorney-in-Fact for Michael L. Blum

Key filing fact

Michael L. Blum filed Form 4 for Homology Medicines, Inc. (QTTB) on 27 Feb 2023.

Key facts

This page summarizes Michael L. Blum's Form 4 filing for Homology Medicines, Inc. (QTTB).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 27 Feb 2023, 15:05.

Change

Previous filing in this sequence was filed on 20 Jan 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FIXX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +104,000
Change %
Price: $0.000000
Shares after: 104,000
Date: 23 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 104,000
Exercise price: $1.60
Footnotes: F1

FIXX transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +17,000
Change %
Price: $0.000000
Shares after: 17,000
Date: 23 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,000
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2023.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date.

Footnote F3

The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2023 so that such RSUs will become fully vested on January 1, 2026.